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Background: Primary spontaneous pneumothorax is commonly treated with chest tube 
insertion, which requires hospitalization. In this study, we evaluated the efficacy, costs, and 
benefits of a portable small-bore chest tube (Thoracic Egg; Sumitomo Bakelite Co. Ltd., 
Tokyo, Japan) compared with a conventional chest tube.
Methods: We retrospectively analyzed all primary spontaneous pneumothorax patients 
who underwent treatment at Gangnam Severance Hospital between August 2014 and 
May 2018.
Results: A total of 279 patients were divided into 2 groups: the conventional group 
(n=236) and the Thoracic Egg group (n=43). Of the 236 patients in the conventional group, 
100 were excluded because they underwent surgery during the study period. The efficacy 
and cost were compared between the 2 groups. There was no statistically significant differ-
ence between the groups regarding recurrence (conventional group, 36 patients [26.5%]; 
Thoracic Egg group, 15 patients [29.4%]; p=0.287). However, the Egg group had statistically 
significantly lower mean medical expenses than the conventional group (433,413 Korean 
won and 522,146 Korean won, respectively; p<0.001).
Conclusion: Although portable small-bore chest tubes may not be significantly more 
efficacious than conventional chest tubes, their use is significantly less expensive. We be-
lieve that the Thoracic Egg catheter could be a less costly alternative to conventional chest 
tube insertion.
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Introduction
Pneumothorax is a condition characterized by the pres-
ence of air in the pleural space. Its occurrence is generally 
spontaneous, post-traumatic, or iatrogenic. Primary spon-
taneous pneumothorax (PSP) occurs in young individuals 
without lung disease, whereas secondary spontaneous 
pneumothorax (SSP) occurs in patients with clinical or ra-
diological evidence of underlying lung disease, particularly 
in those with chronic obstructive pulmonary disease [1]. 
Although PSP generally has a shorter recovery time and a 
better prognosis than SSP, choosing the appropriate treat-
ment method (i.e., surgery or conservative treatment) is 
crucial, as it depends solely on the patient’s situation [2,3].
At many institutions, the standard treatment method for 
PSP is chest tube insertion, which requires hospitalization. 
However, this treatment method is controversial. Accord-
ing to the British Thoracic Society guidelines, performing 
needle aspiration first reduces hospitalization time and 
healthcare costs for PSP patients [3]. The American College 
of Chest Physicians recommends hospitalization after chest 
tube insertion, regardless of tube size, for clinically stable 
patients with large pneumothoraces [2]. The Japan Society 
for Pneumothorax and Cystic Lung Diseases Guidelines 
Committee has not reached a full consensus on this matter 
and currently recommends a variety of options [4].
In the present study, we evaluated the efficacy, costs, and 
benefits of portable small-bore chest tube (Thoracic Egg; 
Sumitomo Bakelite Co. Ltd., Tokyo, Japan) treatment for 
PSP without hospitalization and compared them with 







In this retrospective study, which took place after the in-
troduction of the Thoracic Egg catheter (TEC) in Korea, 
we analyzed the medical records of all patients who visited 
the emergency department or the outpatient clinic of the 
thoracic surgery department and were diagnosed with 
first-time PSP between August 2014 and May 2018. These 
patients were given the choice between CCT insertion with 
hospitalization and TEC insertion via a portable small-
bore chest tube without hospitalization. The patients made 
this decision after they were provided with careful expla-
nations of the advantages and disadvantages of each meth-
od. Based on their choice, patients were divided into either 
the CCT group or the TEC group for a comparative analy-
sis. Patients with SSP, recurrent PSP, signs of pleural effu-
sion or hemothorax on chest X-rays, or hemodynamic in-
stability were excluded from the present study. Medical 
records, including patient characteristics and outpatient 
records and images, were reviewed and analyzed. This 
study was reviewed and approved by the Institutional Eth-
ics Committee and Review Board of Gangnam Severance 
Hospital (IRB approval no., 3-2018-0261). The requirement 
for informed consent was waived due to the retrospective 
nature of the analysis. The TEC was approved by the Kore-
an Ministry of Food and Drug Safety in December 2016 
and has been used in Japan for the past 20 years.
In cases where patients chose CCT with hospitalization 
(the CCT group), a 12F catheter (Argyle suture rib trocar 
catheter; Covidien, Mansfield, MA, USA) was inserted at 
the fifth intercostal space on the anterior axillary line prior 
to hospitalization. Among these patients, surgery was sub-
sequently performed if prolonged air leakage was observed 
for more than 5 days, if the patient chose surgery due to 
concerns of recurrence, or if lung expansion was unsuc-
cessful according to serial chest X-ray.
In cases where patients instead chose the portable tho-
racic drainage device (the TEC group), the Thoracic Egg 
was applied. The Thoracic Egg consists of a flexible 9F sili-
cone catheter with two 1-way Heimlich valves and a small 
plastic chamber (Fig. 1). In brief, a 5-mm skin incision was 
made under local anesthesia; following a test puncture, a 
catheter was inserted in the third to fifth intercostal space 
on the anterior axillary line. After pleural puncture, the 
needle was removed from the catheter, and the catheter 
was inserted into the thoracic cavity, which was then fixed 
to the chest wall and connected to a plastic chamber using 
adhesive tape. Thirty minutes to 1 hour after Thoracic Egg 
insertion, a chest X-ray examination was performed. Pa-
tients were discharged after (1) confirmation of the posi-
tion of the catheter in the thoracic cavity, (2) resolution of 
symptoms, and (3) confirmation of lung expansion. Pa-
tients were advised to visit our outpatient clinic within 1 
week from discharge, at which time the catheter was re-
moved. The TEC was removed from all patients at the out-
patient clinic; however, patients were admitted as inpatients 
upon request.
In the CCT group, medical expenses were calculated 
based on the total days prior to discharge. In the TEC 
group, medical expenses were calculated by the members 
of the outpatient clinic and emergency department includ-
ing the period until the day of device removal. These ex-
penses included the catheter, which was assigned a cost of 
100,000 Korean won (KRW). In Korea, the cost of the Tho-
racic Egg has not yet been established; hence, we estimated 
the cost based on its usage in Japan.
Descriptive statistics were used to compare the variables 
between the 2 groups, using the chi-square test or the Fish-
er exact test for categorical variables and the Student t-test 
for continuous variables. All statistical analyses were per-
formed using IBM SPSS ver. 21.0 (IBM Corp., Armonk, 
NY, USA).
Results
In this study, a total of 279 patients were included for 
analysis: 236 patients in the CCT group and 43 patients in 
the TEC group. The mean follow-up duration was 24.1 
months in the CCT group and 35.5 months in the TEC 
group. There were no significant differences between the 
CCT and TEC groups with respect to age, sex, body mass 
index, and laterality. Among those in the CCT group, 100 
patients (42.4%) underwent surgery during hospitalization. 
However, no patients in the TEC group underwent surgery. 
The catheter indwelling time was 2.8 days in the CCT 
group and 6.1 days in the TEC group, constituting a statis-
tically significant difference (p<0.001) (Table 1).
To facilitate a better comparison, we excluded patients 
who underwent surgery in the CCT group and compared 
those in the CCT group who only underwent chest tube 
treatment with those in the TEC group with respect to re-
currence during follow-up. We found that 36 patients 
(26.5%) in the CCT group and 15 patients (34.9%) in the 
TEC group experienced recurrence. The difference was not 
statistically significant (p=0.287). However, medical ex-
penses were significantly lower in the TEC group (mean, 
433,413 KRW) than in the CCT group (mean, 522,146 
KRW; p<0.001) (Table 2).
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Many outpatient studies of PSP treatment have been 
conducted. Ho et al. [5] showed that 60% of PSP patients 
underwent successful treatment using needle aspiration or 
a Heimlich valve and 12F chest tube. They also showed 
that there was no statistically significant difference with 
respect to the size of the tube; however, smaller tubes have 
been shown in some previous studies to result in less pain 
and greater stability [5-7]. Therefore, we believe that the 
TEC used in this study is highly suitable for treating PSP.
According to the results of the present study, chest tube 
indwelling time was significantly shorter in the CCT group 
than in the TEC group. This may be attributable to serial 
follow-up and care during the hospitalization of the CCT 
patients. Since the majority of PSP patients in this study 
were in their late teens to mid-20s, the purpose of outpa-
tient follow-up was to minimize patient disconnect with 
everyday life (i.e., school and social life) [4,6,8]. We believe 
the TEC to be highly suitable in such circumstances. Al-
though it may be difficult to precisely calculate the socio-
economic effect or to perform an exact cost-benefit analy-
sis of TEC for the treatment of PSP, we firmly believe that 
this device may be particularly advantageous for younger 
PSP patients without any underlying disease.
Karasaki et al. [6] showed that the TEC had a resolution 
rate of 95.8% and a recurrence rate of 32.9%. Our findings 
were similar, with a resolution rate of 100% and a recur-
rence rate of 29.4%. Moreover, Woo et al. [9] found that 
thoracic egg insertion can provide social and economic 
benefits for patients. In the present study, TEC insertion 
was performed in the emergency department, rather than 
in the outpatient clinic. Despite the added cost of using the 
emergency department, the mean overall medical expenses 
for those in the TEC group were significantly lower than 
that for those in the CCT group.
The TEC has some limitations. Given its thinness, it is 
prone to kinking and may easily become disconnected 
from the chamber [6]. Moreover, it can cause infection 
from self-dressing and insufficient pain control. However, 
there were no such complications in our study, as we pro-
vided patients with thorough education as well as appro-
priate antibiotics and analgesics. It is worth noting that 
this lack of complications may be attributable to the fact 
that our patients were all young and healthy with good 
compliance. Another limitation is that we were unable to 
observe exactly when the lung fully expanded and pneu-
mothorax was completely resolved in patients receiving 
TEC insertion, because their follow-up date depended on 
their availability for a visit to the outpatient clinic. There-
fore, it was difficult to draw an accurate comparison of 
chest tube indwelling time between the TEC and CCT 
groups. In addition, concerns may exist regarding whether 
the location of the TEC interferes with lung expansion, al-
though no cases triggered such concern in this study. An-









Age (yr) 28.3±15.5 27.7±15.2 0.797
Gender (male) 200 (83.0) 41 (95.3) 0.062
Body mass index (kg/m²) 20.20±2.89 20.27±2.96 0.912
Laterality (right:left) 101:135 21:22 0.463
Underwent surgery 100 (42.4) 0 <0.001
Catheter indwelling  
time (day)
2.8±1.2 6.1±2.6 <0.001
Follow-up duration (mo) 24.1±11.6 35.5±12.1 <0.001
Values are presented as mean±standard deviation or number (%).
Table 2. Comparison of recurrence and total costs between groups, 
excluding patients who underwent surgery
Variable
Conventional 










Values are presented as mean±standard deviation or number (%).











other limitation of this study may be the inevitability of se-
lection bias, as it took place at a single institution and 
patients chose to be admitted for treatment or to receive 
treatment at the outpatient clinic. A future, large-scale, 
prospective randomized trial is needed to overcome these 
limitations.
In conclusion, in this study, we found that a portable 
small-bore chest tube may not be significantly more effica-
cious than a CCT. However, given that CCT usage normal-
ly requires hospitalization, while use of a portable small-
bore chest tube does not, the latter produces significantly 
lower medical expenses. Therefore, we believe that the TEC 
could be a less costly alternative to CCT insertion, espe-
cially for young, otherwise healthy PSP patients.
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